TrialSignal transduction and targeted therapy2025

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Yongmei Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.